FDA ask MSD to join blockchain supply chain network
Published on 14/06/19 at 09:36am
The FDA has asked MSD to join a shared permission blockchain network to help track and trace prescription medicines and vaccines distribution in the United States.
Alongside IBM and Walmart, US firm Merck will join the blockchain network to allow for real time monitoring of medical products.
“The proposed network is intended to help reduce the time needed to track and trace inventory; allow timely retrieval of reliable distribution information; increase accuracy of data shared among network members; and help determine the integrity of products in the distribution chain, including whether products are kept at the correct temperature,” IBM said in a statement.
The programme, which has been initiated under the US Drug Supply Chain Act (DSCSA), will help stakeholders establish a permanent and immutable record of the drug supply chain through a blockchain network.
“Our supply chain strategy, planning and logistics are built around the customers and patients we serve,” said Craig Kennedy, Senior Vice President, Supply Chain at MSD. “Reliable and verifiable supply helps improve confidence among all the stakeholders—especially patients—while also strengthening the foundation of our business.”
Louis Goss
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- Merck kidney and uterus cancer treatments granted priority review by FDA
- Top Ten most popular articles on Pharmafile.com this week
- FDA to review MSD’s Keytruda as a first-line lung cancer treatment
- MSD faces delay in C. diff drug approval as FDA requests more data
- FDA committee recommends MSD’s c. diff prevention drug
Comments
This information will helpful peoples who are belongs from pharma. Hope this information will helpful for them. Jack Ponting, who is assisting top assignment writing service uk university students at best price.